Ari sütünün ovaryum kanser hücrelerinin proliferasyonu ve apoptozisi üzerine etkisi

Royal jelly is a natural compound with many biological activities such as antitumor, antibacterial, antiallergic, anticarcinogenic and immunomodulatory. Ovarian cancer ranks fourth among the most common cancer types, and especially epithelial ovarian cancer accounts for approximately 90% of all ovarian malignant diseases. The aim of the present study is to investigate the proliferative or apoptotic effects of different doses and durations of royal jelly on serous type epithelial ovarian cancer, which is the most common epithelial ovarian cancer. For this purpose, cells of the Skov-3 human ovarian adenocarcinoma cell line were grown in McCoy medium and seeded in 6-well plates. Royal jelly was prepared as a stock solution (by dissolving 1000mg royal jelly in 10ml distilled water) and 1mg/ml, 5mg/ml, 10 mg/ml, 20 mg/ml and 50 mg/ml royal jelly doses from the prepared stock solution were added to the medium for 24, 48 and 72 hours. incubated. After the application of royal jelly, after the cell viability test (Tripan Blue), Ki-67 to determine the proliferative effect of royal jelly, active caspase-3 and active PARP-1R expressions to determine its apoptotic effect were examined by immunocytochemical and immunofluorescence methods. In addition, immunocytochemical and immunofluorescent findings were supported by the TUNEL method used for the determination of apoptosis. As a result of the experiments, it was determined that 1mg/ml and 24 hours application of royal jelly did not have any effect on cell proliferation and apoptosis, but generally 50 mg/ml royal jelly for 72 hours inhibited proliferation in cancer cells and induced apoptosis. As a result, it is thought that the use of royal jelly as an alternative treatment for ovarian cancer, both monotherapeutically and in combination, can form the basis for new experimental protocols.